Life Science & Technology Weekly 121 – Shanghai Pharma buys US Cardinal Health’s China business for $557 billion Life Science, Technology
Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma Life Science